Header Logo

Connection

MICHAEL ROBERTSON to Hypersensitivity

Back to Details
This is a "connection" page, showing publications MICHAEL ROBERTSON has written about Hypersensitivity.
MICHAEL ROBERTSON
Connection Strength
0.034
Hypersensitivity
  1. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020 Sep; 7(9):e660-e670.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.